Scotiabank Issues Positive Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price

Agios Pharmaceuticals (NASDAQ:AGIO) had its price target raised by Scotiabank from $51.00 to $53.00 in a research report sent to investors on Friday morning, Benzinga reports. Scotiabank currently has a sector outperform rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on AGIO. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 16th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Raymond James reissued an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $52.33.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded up $0.44 during trading on Friday, hitting $44.87. The company had a trading volume of 672,853 shares, compared to its average volume of 689,661. The firm has a market capitalization of $2.55 billion, a P/E ratio of -6.90, a price-to-earnings-growth ratio of 0.47 and a beta of 0.75. Agios Pharmaceuticals has a one year low of $20.40 and a one year high of $53.28. The stock’s 50-day moving average price is $44.62 and its 200 day moving average price is $42.13.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s revenue was up 28.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.51) earnings per share. On average, research analysts anticipate that Agios Pharmaceuticals will post 7.54 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at $3,368,358. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Nordea Investment Management AB raised its stake in shares of Agios Pharmaceuticals by 13.0% during the 1st quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after purchasing an additional 30,764 shares during the period. Caxton Associates LP bought a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth $1,087,000. Vanguard Group Inc. raised its stake in shares of Agios Pharmaceuticals by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after purchasing an additional 59,851 shares during the period. D. E. Shaw & Co. Inc. raised its stake in shares of Agios Pharmaceuticals by 87.3% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after purchasing an additional 316,100 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Agios Pharmaceuticals by 23.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after purchasing an additional 388,381 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.